NICE Turnaround On Novartis’ Xolair To Be Discussed At Asthma & Copd … – Big News Network.com

NICE Turnaround On Novartis' Xolair To Be Discussed At Asthma & Copd
Big News Network.com
asthma in adults, adolescents and children. The decision comes as a result of a move by Novartis to offer a patient access scheme to discount Xolair's list price. An estimated 65 million people currently suffer from COPD globally with 300 million

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.